{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T14:20:35Z","timestamp":1790778035381,"version":"4.1.0"},"reference-count":34,"publisher":"American Medical Association (AMA)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"<jats:sec id=\"ab-zoi240224-4\"><jats:title>Importance<\/jats:title><jats:p>With the widespread use of immune checkpoint inhibitors (ICIs), concerns about their pregnancy outcomes through maternal exposure have emerged, and clinical comparative data are lacking.<\/jats:p><\/jats:sec><jats:sec id=\"ab-zoi240224-5\"><jats:title>Objective<\/jats:title><jats:p>To assess the risk of pregnancy-, fetal-, and\/or newborn-related adverse outcomes associated with exposure to ICIs compared with exposure to other anticancer agents.<\/jats:p><\/jats:sec><jats:sec id=\"ab-zoi240224-6\"><jats:title>Design, Setting, and Participants<\/jats:title><jats:p>In this cohort study, all reports mentioning a pregnancy-related condition and an antineoplastic agent (Anatomical Therapeutic Chemical classification group L01) used for a cancer indication registered in the World Health Organization international pharmacovigilance database VigiBase up to June 26, 2022, were extracted.<\/jats:p><\/jats:sec><jats:sec id=\"ab-zoi240224-7\"><jats:title>Exposure<\/jats:title><jats:p>Anticancer agents, including ICIs, used during pregnancy for a cancer indication. Immune checkpoint inhibitors included blockers of programmed cell death 1 (PD1) or its ligand (PD-L1) or cytotoxic T-lymphocyte\u2013associated protein 4 (CTLA4).<\/jats:p><\/jats:sec><jats:sec id=\"ab-zoi240224-8\"><jats:title>Main Outcomes and Measures<\/jats:title><jats:p>The main outcome was the reporting odds ratio (ROR) for maternal, fetal, or newborn complications in patients treated with ICIs vs any other anticancer drug. Adverse events, categorized into 45 individual maternofetal adverse outcomes, were directly mapped to Medical Dictionary for Regulatory Activities preferred terms in VigiBase.<\/jats:p><\/jats:sec><jats:sec id=\"ab-zoi240224-9\"><jats:title>Results<\/jats:title><jats:p>A total of 3558 reports (ICI: 91 [2.6%]; other anticancer drugs: 3467 [97.4%]) were included in the analysis. In the ICI group, most reports were from the US (60 [65.9%]), and the mean (SD) patient age was 28.9 (10.2) years; in 24 of 55 reports with data on cancer type (43.6%), patients were treated for melanoma. The molecules involved in the ICI group were anti-PD1 (58 reports [63.7%]), anti-PD1 plus anti-CTLA4 (15 [16.5%]), anti-CTLA4 (13 [14.3%]), anti\u2013PD-L1 (4 [4.4%]), and anti-PD1 plus anti\u2013lymphocyte activation gene 3 (1 [1.1%]). An ICI was used in combination with a non-ICI anticancer agent in 10 participants (11.0%). Compared with other anticancer drugs, none of the 45 adverse outcomes identified were overreported in the group exposed to ICIs. However, preterm birth was significantly overreported for the anti-PD1 plus anti-CTLA4 combination compared with other anticancer drugs (12 of 15 [80.0%] vs 793 of 3452 [23.0%]; ROR, 13.87; 95% CI, 3.90-49.28; <jats:italic>P<\/jats:italic>\u2009&amp;amp;lt;\u2009.001) but not for anti\u2013PD-L1 or anti-CTLA4 monotherapy. Three reports of possibly immune-related maternofetal events were identified: 1 case of maternal antiphospholipid syndrome leading to spontaneous abortion, 1 case of pneumonitis leading to neonatal respiratory distress syndrome and death, and 1 case of transient congenital hypothyroidism.<\/jats:p><\/jats:sec><jats:sec id=\"ab-zoi240224-10\"><jats:title>Conclusions and Relevance<\/jats:title><jats:p>In this cohort study of 91 individuals exposed to ICIs during pregnancy, ICI exposure was not associated with overreporting of specific adverse pregnancy, fetal, and\/or newborn outcomes compared with other anticancer treatments. However, due to possible rare immune-related neonatal adverse events, ICI use in pregnant women should be avoided when possible, especially the anti-PD1 plus anti-CTLA4 combination.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2024.5625","type":"journal-article","created":{"date-parts":[[2024,4,17]],"date-time":"2024-04-17T15:06:14Z","timestamp":1713366374000},"page":"e245625","source":"Crossref","is-referenced-by-count":71,"title":["Immune Checkpoint Inhibitor Use During Pregnancy and Outcomes in Pregnant Individuals and Newborns"],"prefix":"10.1001","volume":"7","author":[{"given":"Paul","family":"Gougis","sequence":"first","affiliation":[{"name":"Residual Tumor and Response to Treatment Laboratory, Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale (INSERM), U932 Immunity and Cancer, Institut Curie, Universit\u00e9 Paris, Paris, France"},{"name":"INSERM, Assistance Publique\u2013H\u00f4pitaux de Paris (AP-HP), Clinical Investigation Center (CIC) 1901, Department of Pharmacology, Piti\u00e9-Salp\u00eatri\u00e8re Hospital, Sorbonne Universit\u00e9, Paris, France"},{"name":"Department of Medical Oncology, AP-HP, Piti\u00e9-Salp\u00eatri\u00e8re Hospital, Institut Universitaire de Canc\u00e9rologie, INSERM U1136, CLIP2 Galil\u00e9e, Sorbonne Universit\u00e9, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Sophie","family":"Hamy","sequence":"additional","affiliation":[{"name":"Residual Tumor and Response to Treatment Laboratory, Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale (INSERM), U932 Immunity and Cancer, Institut Curie, Universit\u00e9 Paris, Paris, France"},{"name":"Department of Medical Oncology, Institut Curie, Universit\u00e9 Paris, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Floriane","family":"Jochum","sequence":"additional","affiliation":[{"name":"Residual Tumor and Response to Treatment Laboratory, Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale (INSERM), U932 Immunity and Cancer, Institut Curie, Universit\u00e9 Paris, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Bihan","sequence":"additional","affiliation":[{"name":"INSERM, Assistance Publique\u2013H\u00f4pitaux de Paris (AP-HP), Clinical Investigation Center (CIC) 1901, Department of Pharmacology, Piti\u00e9-Salp\u00eatri\u00e8re Hospital, Sorbonne Universit\u00e9, Paris, France"},{"name":"Paris Piti\u00e9\u2013St Antoine Regional Pharmacovigilance Center, Medical Pharmacology Department, AP-HP Sorbonne University Hospital Group, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Carbonnel","sequence":"additional","affiliation":[{"name":"INSERM U1135, Centre d\u2019Immunologie et des Maladies Infectieuses\u2013Paris, Sorbonne Universit\u00e9, Paris, France"},{"name":"Department of Obstetrics and Gynecology, Foch Hospital, University of Versailles-Saint-Quentin-en-Yvelines Paris Saclay, Montigny-Le-Bretonneux, Suresnes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joe-Elie","family":"Salem","sequence":"additional","affiliation":[{"name":"INSERM, Assistance Publique\u2013H\u00f4pitaux de Paris (AP-HP), Clinical Investigation Center (CIC) 1901, Department of Pharmacology, Piti\u00e9-Salp\u00eatri\u00e8re Hospital, Sorbonne Universit\u00e9, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elise","family":"Dumas","sequence":"additional","affiliation":[{"name":"Residual Tumor and Response to Treatment Laboratory, Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale (INSERM), U932 Immunity and Cancer, Institut Curie, Universit\u00e9 Paris, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rayan","family":"Kabirian","sequence":"additional","affiliation":[{"name":"Residual Tumor and Response to Treatment Laboratory, Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale (INSERM), U932 Immunity and Cancer, Institut Curie, Universit\u00e9 Paris, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"Grandal","sequence":"additional","affiliation":[{"name":"Residual Tumor and Response to Treatment Laboratory, Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale (INSERM), U932 Immunity and Cancer, Institut Curie, Universit\u00e9 Paris, Paris, France"},{"name":"Department of Breast, Gynecological and Reconstructive Surgery, Institut Curie, Universit\u00e9 Paris, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Solenn","family":"Barraud","sequence":"additional","affiliation":[{"name":"Residual Tumor and Response to Treatment Laboratory, Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale (INSERM), U932 Immunity and Cancer, Institut Curie, Universit\u00e9 Paris, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Coussy","sequence":"additional","affiliation":[{"name":"Residual Tumor and Response to Treatment Laboratory, Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale (INSERM), U932 Immunity and Cancer, Institut Curie, Universit\u00e9 Paris, Paris, France"},{"name":"Department of Medical Oncology, Institut Curie, Universit\u00e9 Paris, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judicael","family":"Hotton","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, Institut Godinot, Reims, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raphaelle","family":"Savarino","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Institut Curie, Universit\u00e9 Paris, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aur\u00e9lien","family":"Marabelle","sequence":"additional","affiliation":[{"name":"D\u00e9partement d\u2019Innovation Th\u00e9rapeutique et d\u2019Essais Pr\u00e9coces, Gustave Roussy, D\u00e9partement de M\u00e9decine Interne et Immunologie clinique, AP-HP, H\u00f4pital Universitaire Bic\u00eatre, INSERM U1015 and CIC1428, Le Kremlin Bic\u00eatre, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques","family":"Cadranel","sequence":"additional","affiliation":[{"name":"Department of Pneumology, AP-HP, Tenon Hospital, Institut Universitaire de Canc\u00e9rologie, Sorbonne Universit\u00e9, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Philippe","family":"Spano","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, AP-HP, Piti\u00e9-Salp\u00eatri\u00e8re Hospital, Institut Universitaire de Canc\u00e9rologie, INSERM U1136, CLIP2 Galil\u00e9e, Sorbonne Universit\u00e9, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enora","family":"Laas","sequence":"additional","affiliation":[{"name":"Residual Tumor and Response to Treatment Laboratory, Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale (INSERM), U932 Immunity and Cancer, Institut Curie, Universit\u00e9 Paris, Paris, France"},{"name":"Department of Breast, Gynecological and Reconstructive Surgery, Institut Curie, Universit\u00e9 Paris, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabien","family":"Reyal","sequence":"additional","affiliation":[{"name":"Residual Tumor and Response to Treatment Laboratory, Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale (INSERM), U932 Immunity and Cancer, Institut Curie, Universit\u00e9 Paris, Paris, France"},{"name":"Department of Breast, Gynecological and Reconstructive Surgery, Institut Curie, Universit\u00e9 Paris, Paris, France"},{"name":"Department of Surgical Oncology, Institut Godinot, Reims, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baptiste","family":"Abbar","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, AP-HP, Piti\u00e9-Salp\u00eatri\u00e8re Hospital, Institut Universitaire de Canc\u00e9rologie, INSERM U1136, CLIP2 Galil\u00e9e, Sorbonne Universit\u00e9, Paris, France"},{"name":"INSERM U1135, Centre d\u2019Immunologie et des Maladies Infectieuses\u2013Paris, Sorbonne Universit\u00e9, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2024,4,17]]},"reference":[{"issue":"1","key":"zoi240224r1","doi-asserted-by":"publisher","first-page":"28","DOI":"10.14740\/wjon1177","article-title":"Cancer during pregnancy: the oncologist overview.","volume":"10","author":"Hepner","year":"2019","journal-title":"World J Oncol"},{"issue":"4","key":"zoi240224r2","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1634\/theoncologist.2002-0279","article-title":"Coexistence of pregnancy and malignancy.","volume":"7","author":"Pavlidis","year":"2002","journal-title":"Oncologist"},{"issue":"3","key":"zoi240224r3","doi-asserted-by":"publisher","first-page":"738","DOI":"10.3390\/cancers12030738","article-title":"Review of indications of FDA-approved immune checkpoint inhibitors per NCCN guidelines with the level of evidence.","volume":"12","author":"Vaddepally","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"1","key":"zoi240224r4","doi-asserted-by":"publisher","first-page":"3801","DOI":"10.1038\/s41467-020-17670-y","article-title":"A decade of immune-checkpoint inhibitors in cancer therapy.","volume":"11","author":"Robert","year":"2020","journal-title":"Nat Commun"},{"key":"zoi240224r5","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1146\/pharmtox.2021.61.issue-1","article-title":"Clinical pharmacology and interplay of immune checkpoint agents: a yin-yang balance.","volume":"61","author":"Geraud","year":"2021","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"zoi240224r6","doi-asserted-by":"publisher","first-page":"2729","DOI":"10.3389\/fimmu.2019.02729","article-title":"Editorial: fetal-maternal immune interactions in pregnancy.","volume":"10","author":"Than","year":"2019","journal-title":"Front Immunol"},{"issue":"9","key":"zoi240224r7","doi-asserted-by":"publisher","first-page":"4530","DOI":"10.4049\/jimmunol.1002031","article-title":"The link between the PDL1 costimulatory pathway and Th17 in fetomaternal tolerance.","volume":"187","author":"D\u2019Addio","year":"2011","journal-title":"J Immunol"},{"issue":"8","key":"zoi240224r8","doi-asserted-by":"publisher","first-page":"5211","DOI":"10.4049\/jimmunol.179.8.5211","article-title":"A link between PDL1 and T regulatory cells in fetomaternal tolerance.","volume":"179","author":"Habicht","year":"2007","journal-title":"J Immunol"},{"issue":"2","key":"zoi240224r9","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1084\/jem.20050019","article-title":"A critical role for the programmed death ligand 1 in fetomaternal tolerance.","volume":"202","author":"Guleria","year":"2005","journal-title":"J Exp Med"},{"issue":"12","key":"zoi240224r10","doi-asserted-by":"publisher","first-page":"e550","DOI":"10.1016\/S1470-2045(21)00525-8","article-title":"Immunotherapy for cancer treatment during pregnancy.","volume":"22","author":"Borgers","year":"2021","journal-title":"Lancet Oncol"},{"issue":"24","key":"zoi240224r11","doi-asserted-by":"publisher","first-page":"5249","DOI":"10.1158\/1078-0432.CCR-22-1110","article-title":"FDA approval summary: pembrolizumab for neoadjuvant and adjuvant treatment of patients with high-risk early-stage triple-negative breast cancer.","volume":"28","author":"Shah","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"6","key":"zoi240224r12","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1007\/s12094-020-02491-8","article-title":"Multidisciplinary consensus on cancer management during pregnancy.","volume":"23","author":"Cubillo","year":"2021","journal-title":"Clin Transl Oncol"},{"issue":"5","key":"zoi240224r14","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1177\/009286150804200501","article-title":"VigiBase, the WHO Global ICSR Database System: basic facts.","volume":"42","author":"Lindquist","year":"2008","journal-title":"Ther Innov Regul Sci"},{"issue":"38","key":"zoi240224r15","doi-asserted-by":"publisher","first-page":"3915","DOI":"10.1093\/eurheartj\/ehab362","article-title":"Anticancer drug-induced life-threatening ventricular arrhythmias: a World Health Organization pharmacovigilance study.","volume":"42","author":"Salem","year":"2021","journal-title":"Eur Heart J"},{"issue":"6","key":"zoi240224r16","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00038-2020","article-title":"Increased reporting of fatal pneumonitis associated with immune checkpoint inhibitors: a WHO pharmacovigilance database analysis.","volume":"55","author":"Moey","year":"2020","journal-title":"Eur Respir J"},{"issue":"1","key":"zoi240224r18","doi-asserted-by":"publisher","first-page":"173","DOI":"10.3390\/cancers15010173","article-title":"Immune checkpoint inhibitors and pregnancy: analysis of the VigiBase Spontaneous Reporting System.","volume":"15","author":"Noseda","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"10","key":"zoi240224r19","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.39934","article-title":"Treatments during pregnancy targeting ERBB2 and outcomes of pregnant individuals and newborns.","volume":"6","author":"Gougis","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"1","key":"zoi240224r20","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1186\/s12885-021-08162-3","article-title":"Trastuzumab administration during pregnancy: an update.","volume":"21","author":"Andrikopoulou","year":"2021","journal-title":"BMC Cancer"},{"issue":"2","key":"zoi240224r21","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/s10549-012-2368-y","article-title":"Trastuzumab administration during pregnancy: a systematic review and meta-analysis.","volume":"137","author":"Zagouri","year":"2013","journal-title":"Breast Cancer Res Treat"},{"key":"zoi240224r22","doi-asserted-by":"publisher","first-page":"S31","DOI":"10.4103\/sja.SJA_543_18","article-title":"The STROBE guidelines.","volume":"13","author":"Cuschieri","year":"2019","journal-title":"Saudi J Anaesth"},{"issue":"6","key":"zoi240224r23","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1016\/j.therap.2020.02.022","article-title":"Uses of pharmacovigilance databases: an overview.","volume":"75","author":"Bihan","year":"2020","journal-title":"Therapie"},{"issue":"5","key":"zoi240224r24","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100262","article-title":"Immune checkpoint inhibitor administration during pregnancy: a case series.","volume":"6","author":"Andrikopoulou","year":"2021","journal-title":"ESMO Open"},{"issue":"19","key":"zoi240224r25","doi-asserted-by":"publisher","first-page":"1790","DOI":"10.1056\/NEJMoa2308135","article-title":"Severe immune-related enteritis after in utero exposure to pembrolizumab.","volume":"389","author":"Baarslag","year":"2023","journal-title":"N Engl J Med"},{"issue":"10","key":"zoi240224r26","doi-asserted-by":"publisher","first-page":"e1883","DOI":"10.1002\/onco.13941","article-title":"Outcomes of pregnancy during immunotherapy treatment for cancer: analysis of clinical trials sponsored by the National Cancer Institute.","volume":"26","author":"Mittra","year":"2021","journal-title":"Oncologist"},{"issue":"3","key":"zoi240224r27","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.1611","article-title":"Immune checkpoint inhibitors and immune-related adverse events in patients with advanced melanoma: a systematic review and network meta-analysis.","volume":"3","author":"Chang","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"1","key":"zoi240224r28","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1186\/s40425-019-0779-6","article-title":"Incidence rates of immune-related adverse events and their correlation with response in advanced solid tumours treated with NIVO or NIVO+IPI: a systematic review and meta-analysis.","volume":"7","author":"Xing","year":"2019","journal-title":"J Immunother Cancer"},{"issue":"5","key":"zoi240224r29","doi-asserted-by":"publisher","DOI":"10.1111\/aji.2018.79.issue-5","article-title":"Placenta immune infiltrates and perinatal outcomes.","volume":"79","author":"Ozen","year":"2018","journal-title":"Am J Reprod Immunol"},{"key":"zoi240224r30","doi-asserted-by":"publisher","first-page":"125","DOI":"10.3389\/fimmu.2014.00125","article-title":"Innate and adaptive immune interactions at the fetal-maternal interface in healthy human pregnancy and pre-eclampsia.","volume":"5","author":"Hsu","year":"2014","journal-title":"Front Immunol"},{"issue":"3","key":"zoi240224r31","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1111\/aji.2015.74.issue-3","article-title":"Recent insight into the role of the PD-1\/PD-L1 pathway in feto-maternal tolerance and pregnancy.","volume":"74","author":"Zhang","year":"2015","journal-title":"Am J Reprod Immunol"},{"issue":"5899","key":"zoi240224r32","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1126\/science.1160062","article-title":"CTLA-4 control over Foxp3+ regulatory T cell function.","volume":"322","author":"Wing","year":"2008","journal-title":"Science"},{"issue":"1","key":"zoi240224r33","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2019.101463","article-title":"Antiphospholipid syndrome.","volume":"34","author":"Sammaritano","year":"2020","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"2","key":"zoi240224r34","doi-asserted-by":"publisher","first-page":"113","DOI":"10.14310\/horm.2002.1149","article-title":"Transient congenital hypothyroidism due to maternal autoimmune thyroid disease.","volume":"2","author":"Mengreli","year":"2003","journal-title":"Hormones (Athens)"},{"key":"zoi240224r17"},{"key":"zoi240224r13","unstructured":"Keytruda. Prescribing information. October 23, 2023. Accessed October 23, 2023. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/125514s139lbl.pdf"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2817708\/gougis_2024_oi_240224_1712767387.39005.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,17]],"date-time":"2024-04-17T15:06:18Z","timestamp":1713366378000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2817708"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,17]]},"references-count":34,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.5625","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,17]]}}}